Free Word download • Edit online • Save & share with Drive • Export to PDF
A Technology Transfer Agreement is a legally binding contract through which the owner of a technology — including patents, proprietary software, trade secrets, or technical know-how — grants defined rights to another party to use, develop, or commercialize that technology. The agreement can take the form of a license (where the original owner retains title) or an assignment (where ownership itself passes permanently to the other party). It specifies the scope of rights granted, the territory and field of use, royalty or payment terms, sublicensing permissions, and the obligations each party bears to protect confidential technical information. Technology transfer agreements are the commercial backbone of university spin-outs, pharma licensing deals, software OEM relationships, and cross-border manufacturing joint ventures.
Without a written technology transfer agreement, valuable IP can change hands with no enforceable record of who owns what, who owes royalties to whom, or what happens when the relationship ends. A verbal understanding falls apart the moment a key employee leaves, a company is acquired, or a royalty dispute arises — and courts will not supply missing terms in complex IP transactions. The cost of an undocumented transfer is severe: an undocumented transferee may be unable to enforce the patents it believed it owned; an undocumented transferor may lose all control over how its technology is sublicensed or modified. For any technology with real commercial value, a properly executed agreement protects both sides — confirming the transferor's right to receive royalties, the transferee's right to operate without infringement claims, and both parties' rights over improvements made after signing.
| If your situation is… | Use this template |
|---|---|
| Licensing technology while retaining ownership and allowing royalties | Technology License Agreement |
| Permanently transferring all ownership rights to the technology | IP Assignment Agreement |
| Sharing know-how and processes between joint-venture partners | Joint Development Agreement |
| Allowing use of software source code under defined conditions | Software License Agreement |
| Disclosing technology details before a full agreement is signed | Non-Disclosure Agreement |
| Transferring technology across international borders with customs implications | International Technology Transfer Agreement |
| Licensing patented technology in exchange for cross-licensing rights | Cross-License Agreement |
Why it matters: If the agreement does not precisely identify what is being transferred, either party can later dispute whether a specific patent, algorithm, or process was included — creating expensive litigation over the agreement's basic scope.
Fix: Attach detailed schedules listing every patent by number, every software component by version, and every trade-secret category by written description before execution.
Why it matters: Granting an exclusive license without a field-of-use limit can inadvertently block the transferor from commercializing the same technology in adjacent industries, even if the parties never discussed that restriction.
Fix: Always define the field of use in a schedule when granting exclusive rights. If the intent is truly unrestricted, state 'all fields of use' explicitly so there is no ambiguity.
Why it matters: Royalties calculated on gross revenue before returns, taxes, and distributor discounts can double or triple the effective royalty rate the transferee expected, triggering disputes that unwind deals.
Fix: Define 'Net Sales' to explicitly exclude returns, rebates, chargebacks, sales taxes, freight, and insurance before calculating the royalty percentage.
Why it matters: When the transferee improves the technology substantially, undefined ownership makes it impossible to enforce, license, or sell the improved version without the other party's cooperation — or a lawsuit.
Fix: Include an improvements clause covering sole improvements, joint improvements, and grant-back rights. Address this before signing, not after the first valuable enhancement is made.
Why it matters: Transferring controlled technology to a foreign entity or non-US person without the required US government authorization is a criminal offense under EAR and ITAR, regardless of whether the parties intended to comply.
Fix: Add an export control clause requiring both parties to identify applicable controls, obtain necessary licenses, and provide written representations about restricted-party status before any technology disclosure.
Why it matters: If the main agreement terminates and sublicenses automatically terminate with it, the transferee's downstream customers lose operating rights overnight — creating immediate breach-of-contract claims against the transferee.
Fix: Include a survival clause for existing sublicenses on termination where the sublicensee is not itself in breach, or explicitly state that all sublicenses terminate with the main agreement so both parties plan accordingly.
In plain language: Identifies the transferor and transferee by full legal name, states the commercial context of the deal, and defines all key terms used throughout the agreement.
This Technology Transfer Agreement ('Agreement') is entered into as of [DATE] by and between [TRANSFEROR LEGAL NAME], a [STATE/COUNTRY] [ENTITY TYPE] ('Transferor'), and [TRANSFEREE LEGAL NAME], a [STATE/COUNTRY] [ENTITY TYPE] ('Transferee'). Transferor owns certain proprietary technology described herein and desires to transfer rights thereto to Transferee on the terms set forth below.
Common mistake: Using a trade name instead of the registered legal entity for either party. If the entity name does not match ownership records for the IP, the grant of rights may not effectively transfer anything.
In plain language: Precisely describes the technology being transferred — patents by number, software by version, trade secrets by category — and attaches supporting schedules.
The 'Licensed Technology' means: (a) the patents and patent applications listed in Schedule A; (b) the software codebase identified in Schedule B, version [VERSION NUMBER]; and (c) the technical know-how and documentation described in Schedule C, as updated by written agreement of the parties.
Common mistake: Describing the technology in vague commercial terms (e.g., 'our AI platform') rather than by specific patent numbers, version identifiers, or documented trade-secret categories. Vague descriptions create scope disputes the moment either party wants to expand or enforce the agreement.
In plain language: States whether the license is exclusive or non-exclusive, the geographic territory, the field of use, and whether sublicensing is permitted.
Subject to the terms of this Agreement, Transferor hereby grants to Transferee a [exclusive / non-exclusive], [sublicensable / non-sublicensable], worldwide [or: limited to TERRITORY] license to use, reproduce, modify, and commercialize the Licensed Technology solely within the Field of Use defined in Schedule D.
Common mistake: Omitting a field-of-use restriction when the transferor intends to license the same technology to other parties in adjacent markets. Without it, an exclusive grant can inadvertently block the transferor's own commercialization plans.
In plain language: Sets out the upfront fee, ongoing royalty rate, royalty base, payment schedule, reporting obligations, and any milestone-triggered lump sums.
Transferee shall pay Transferor: (a) an upfront license fee of $[AMOUNT] due within [30] days of execution; (b) a running royalty of [X]% of Net Sales of Licensed Products in each calendar quarter, payable within [45] days of quarter-end; and (c) milestone payments as set out in Schedule E upon achievement of each milestone.
Common mistake: Defining 'Net Sales' without excluding returns, chargebacks, taxes, and distributor discounts. An ambiguous royalty base is the most common source of post-signing financial disputes in technology licensing.
In plain language: Determines whether the transferee may grant sublicenses to third parties and, if so, under what conditions — including whether sublicense royalties flow back to the transferor.
Transferee may grant sublicenses to the Licensed Technology only with Transferor's prior written consent, which shall not be unreasonably withheld. Each sublicense shall be consistent with this Agreement, and Transferee shall remain jointly and severally liable for sublicensee compliance. [X]% of all sublicense fees received by Transferee shall be paid to Transferor within [30] days of receipt.
Common mistake: Granting broad sublicensing rights without requiring sublicensees to sign agreements at least as protective as the main agreement. A sublicensee data breach or IP misuse can expose the transferor without any contractual recourse.
In plain language: Allocates ownership of modifications or enhancements made to the licensed technology after signing and defines whether a grant-back to the transferor is required.
All Improvements to the Licensed Technology made solely by Transferee shall be owned by Transferee. Transferee hereby grants to Transferor a non-exclusive, royalty-free license to use any such Improvements for Transferor's internal purposes. Jointly developed Improvements shall be jointly owned with each party free to exploit without accounting to the other.
Common mistake: No improvements clause at all. When a transferee significantly enhances the technology, undefined ownership creates deadlock on further development, commercialization, and enforcement against third-party infringers.
In plain language: Requires both parties to protect non-public technical information, trade secrets, and know-how disclosed under the agreement for a defined period.
Each party shall hold the other's Confidential Information in strict confidence using at least the same degree of care it applies to its own confidential information, but no less than reasonable care. This obligation survives termination of this Agreement for a period of [5] years.
Common mistake: Setting a confidentiality term that expires before commercially significant trade secrets lose their value. For manufacturing processes or proprietary algorithms, a 2-year post-termination period may be far too short.
In plain language: The transferor warrants that it owns or has rights to the technology and that the transfer does not infringe third-party IP; the transferee warrants it has authority to enter the agreement.
Transferor represents and warrants that: (a) it is the sole owner of the Licensed Technology free and clear of all liens and encumbrances; (b) to Transferor's knowledge, the Licensed Technology does not infringe any third-party intellectual property rights; and (c) Transferor has full authority to enter this Agreement.
Common mistake: Including a warranty of non-infringement on an absolute rather than knowledge-qualified basis. Universities and research institutions in particular routinely insist on 'to Transferor's knowledge' qualifiers because a comprehensive freedom-to-operate search is rarely complete at signing.
In plain language: Defines the conditions under which either party may terminate — breach, insolvency, change of control — and what happens to the technology, sublicenses, and payments afterward.
Either party may terminate this Agreement upon [30] days' written notice if the other party materially breaches and fails to cure within [30] days. Upon termination: (a) all licenses granted herein immediately cease; (b) Transferee shall destroy or return all Confidential Information; and (c) accrued royalties due as of the termination date remain payable.
Common mistake: Not addressing the fate of existing sublicenses on termination. If the main agreement ends, do sublicenses automatically terminate or survive? Silence on this point can expose sublicensees — and the transferee — to sudden loss of operating rights.
In plain language: Specifies the applicable law and forum for disputes and acknowledges export-control compliance obligations for technology with international applications.
This Agreement is governed by the laws of [STATE / JURISDICTION]. Any dispute shall be resolved by binding arbitration before [AAA / ICC] in [CITY], except claims for injunctive relief. Each party agrees to comply with all applicable export control laws, including the US Export Administration Regulations (EAR) and ITAR where applicable.
Common mistake: Omitting the export control clause entirely when the technology has military, dual-use, or encryption components. Transferring controlled technology to a foreign national or foreign entity without the required US government license is a federal criminal offense.
Enter the full registered legal names and jurisdictions of both the transferor and transferee. Before signing, confirm the transferor holds clear title to every element of the licensed technology — check patent assignment records at the USPTO and corporate IP assignment agreements with employees and contractors.
💡 Run a quick USPTO assignment database search on the patent numbers in Schedule A to confirm recorded ownership matches the transferor entity named in the agreement.
Draft Schedule A listing each patent by number, Schedule B identifying software by version and repository hash, and Schedule C describing trade secrets and know-how by category. Attach all schedules before execution.
💡 For software transfers, include a SHA-256 hash of the specific codebase version in Schedule B — this creates an immutable record of exactly what was transferred and when.
Decide whether the grant is exclusive or non-exclusive, worldwide or territory-limited, and whether sublicensing is permitted. Draft a field-of-use schedule if the transferor intends to retain rights in adjacent markets.
💡 If you are granting an exclusive license, confirm you have no existing non-exclusive licenses to the same technology that would conflict — check all prior agreements before drafting.
Enter the upfront fee, royalty rate, and the definition of Net Sales that the royalty applies to. Explicitly exclude returns, taxes, and distributor allowances from the royalty base. Add milestone payment triggers in Schedule E.
💡 Benchmark your royalty rate against published industry standards — pharmaceutical licenses typically run 3–10% of net sales; software licenses often use a flat per-seat fee instead of a percentage.
Decide whether the transferee may sublicense and under what approval process. Allocate ownership of improvements — sole, joint, or grant-back — and confirm both parties understand the implications before finalizing the language.
💡 If the transferee will sublicense to distributors, require a standard sublicense agreement form as an exhibit so every sublicense is automatically consistent with the main agreement.
Set the confidentiality standard, the categories of excluded information, and the post-termination survival period. For core trade secrets, consider a perpetual confidentiality obligation rather than a fixed term.
💡 Specify in writing which employees and contractors of each party are permitted to access confidential technical information — limiting access by role reduces leak risk and strengthens enforceability.
Define termination triggers (material breach, insolvency, change of control), the cure period, and what happens to sublicenses and accrued royalties post-termination. If any element of the technology is subject to EAR, ITAR, or EU dual-use controls, add the export compliance clause.
💡 Consult an export control attorney before finalizing any transfer involving encryption software, defense-related hardware, or technology licensed to a foreign national — even a royalty-free academic license can require government approval.
Both parties must sign before any confidential technical information, source code, or patent documentation is shared. Post-disclosure signatures create enforceability gaps, particularly on confidentiality and IP ownership.
💡 Use a timestamp-verified eSignature platform and store the fully executed agreement alongside all schedules in a single version-controlled file to prevent schedule substitution disputes.
A technology transfer agreement is a legally binding contract through which the owner of a technology — such as a patent, software platform, or proprietary manufacturing process — grants defined rights to another party to use, develop, or commercialize that technology. The rights granted can be exclusive or non-exclusive, limited by territory or field of use, and can cover a license (where the transferor retains ownership) or a full assignment (where ownership itself transfers). These agreements are commonly used between corporations, universities, and research institutions when commercializing IP.
The terms are often used interchangeably, but there is a meaningful distinction. A technology license agreement grants rights to use the technology while the transferor retains ownership. A technology transfer agreement can encompass both licenses and outright assignments of ownership. When the full title to a patent or software codebase passes from one party to another permanently, an IP assignment agreement is the more precise instrument — though many commercial parties use "technology transfer agreement" to cover both scenarios.
Yes. In virtually every jurisdiction, an exclusive patent license or IP assignment must be in writing to be enforceable — the US Patent Act, the Canadian Patent Act, and the UK Patents Act all require written instruments for assignments and exclusive licenses. Non-exclusive licenses can theoretically be oral in some jurisdictions, but oral technology agreements are essentially unenforceable in practice due to the complexity of defining scope, royalties, and ownership. A written agreement is always required.
The most common structures are a percentage of net sales (running royalty), a fixed fee per unit or per seat, a lump-sum upfront payment, or a combination of an upfront fee plus a lower running royalty rate. Industry rates vary widely: pharmaceutical and biotech licenses typically run 3–10% of net sales; software licenses often use per-seat or per-transaction fees. Milestone payments — lump sums triggered by regulatory approval, first commercial sale, or revenue thresholds — are standard in life-sciences and hardware deals.
A field-of-use restriction limits the transferee's right to use the licensed technology to a specific industry, application, or purpose. For example, a university might license the same diagnostic technology to one company for human diagnostics and to another for veterinary applications — each with an exclusive field-of-use license in their respective fields. Without a field-of-use clause, an exclusive license can inadvertently block the transferor from licensing the same technology to other parties in adjacent markets, significantly reducing the technology's total commercial value.
Yes. Technology transfer agreements typically include termination rights for material breach (with a cure period), insolvency, or change of control. Some agreements also give the transferee a right to terminate for convenience with advance notice. The consequences of termination — cessation of licenses, return of confidential information, survival of accrued royalties, and the fate of existing sublicenses — must all be addressed explicitly in the agreement.
If the transferred technology is subject to US Export Administration Regulations (EAR), the International Traffic in Arms Regulations (ITAR), or EU dual-use export controls, the parties must obtain the required government authorizations before transferring technical data to foreign nationals or foreign entities. This applies even to academic and research transfers. Failure to comply is a federal criminal offense in the US with penalties of up to $1 million per violation. An export control attorney should review any transfer involving encryption, defense-adjacent, or advanced semiconductor technologies.
University technology transfer offices commercializing faculty research, startups spinning out core IP into a new entity, corporations acquiring or licensing technology from acquisition targets, software companies licensing platforms to OEM and distribution partners, and manufacturers sharing patented production processes with international joint-venture partners all routinely use technology transfer agreements. Any situation where valuable technical IP changes hands — or is licensed for commercial use — warrants a formal written agreement.
For straightforward domestic non-exclusive licenses involving low-risk technology and modest royalties, a well-structured template reviewed by an IP attorney is typically sufficient. Lawyer involvement is strongly recommended for exclusive licenses, transfers involving patents or regulated technology, cross-border transactions, university licensing, deals with milestone payments exceeding $100,000, and any transaction where export controls may apply. A 2–4 hour IP attorney review typically costs $600–$1,500 and is a sound investment relative to the value of the technology at stake.
An IP assignment agreement permanently transfers full ownership of the technology from the assignor to the assignee — after signing, the original owner retains no rights. A technology transfer agreement typically grants a license while the transferor retains ownership, or can combine an assignment with ongoing service and royalty obligations. Use an assignment when the intent is a clean, permanent sale of the IP and no ongoing relationship is needed.
A software license agreement grants end-user or OEM rights to use a software product, typically without disclosing source code or technical know-how. A technology transfer agreement is broader — it can include source code, patents, trade secrets, and embedded documentation, and it often involves royalty sharing and improvement rights. Use a software license for product distribution; use a technology transfer agreement when the underlying technical architecture and IP is itself the subject of the deal.
An NDA protects confidential information during evaluation and negotiation but does not grant any rights to use or commercialize the technology. A technology transfer agreement both grants the rights and includes confidentiality obligations. An NDA is typically signed first, before technical details are disclosed; the technology transfer agreement follows once terms are agreed and formalizes the commercial relationship.
A joint development agreement governs the collaborative creation of new technology between two parties, allocating ownership of outputs and background IP each party brings in. A technology transfer agreement deals with existing technology that one party already owns and is transferring or licensing to the other. If the parties plan to build something new together, use a joint development agreement; if one party is licensing what it already has, use a technology transfer agreement.
Patent portfolio transfers with milestone payments tied to clinical trial phases, FDA approval, and first commercial sale; royalty stacking provisions where multiple technology licenses underlie a single product.
Source-code escrow requirements, version-specific licensing schedules, per-seat or per-API-call royalty structures, and open-source license compliance representations.
Know-how transfer protocols requiring on-site technical assistance, production process documentation in Schedule C, and export control screening for dual-use equipment and materials.
Bayh-Dole Act compliance for federally funded inventions, publication rights preservation clauses, equity stakes in lieu of upfront fees, and retained research use licenses.
US patent assignments and exclusive licenses must be in writing under 35 U.S.C. § 261 to be enforceable against third parties. Technology originating from federally funded research is subject to the Bayh-Dole Act, which requires preferential licensing to US manufacturers and government march-in rights. Export-controlled technology must comply with EAR (15 C.F.R. Parts 730–774) and ITAR (22 C.F.R. Parts 120–130) before any transfer to a foreign national or entity, even within the US.
Canadian patent assignments and exclusive licenses must be in writing and registered with the Canadian Intellectual Property Office (CIPO) to be effective against subsequent transferees. Quebec-based parties must ensure the agreement is available in French for provincially regulated entities. Canada's Export and Import Permits Act (EIPA) and the Controlled Goods Program govern transfers of dual-use and defense-related technology to foreign parties.
Under the UK Patents Act 1977, patent assignments must be in writing and signed by or on behalf of the assignor to be valid. Exclusive licensees in the UK have standing to bring infringement proceedings in their own name, which is a meaningful commercial consideration when negotiating exclusivity. Post-Brexit, the UK operates its own export licensing regime under the Export Control Order 2008, separate from EU dual-use controls.
Technology transfer agreements within the EU may benefit from the Technology Transfer Block Exemption Regulation (TTBER, Regulation 316/2014), which provides a safe harbor from EU competition law for licensing between non-competing parties with combined market share below 20% or competing parties below 20% each. GDPR applies where the technology involves personal data processing. EU dual-use export controls (Regulation 2021/821) require authorization for transfers of listed technologies to non-EU countries.
| Path | Best for | Cost | Time |
|---|---|---|---|
| Use the template | Domestic non-exclusive licenses of low-risk technology with straightforward royalty structures and no export control implications | Free | 1–2 hours |
| Template + legal review | Exclusive licenses, patent-heavy transfers, cross-border deals, university spin-outs, or transactions with milestone payments above $50,000 | $600–$1,500 (IP attorney review, 2–4 hours) | 3–7 days |
| Custom drafted | Complex pharmaceutical or biotech licenses, ITAR/EAR-controlled technology transfers, multi-patent portfolios, or transactions with total royalty value above $1 million | $3,000–$15,000+ | 2–6 weeks |
This document is one of 3,000+ business & legal templates included in Business in a Box.
Access over 3,000+ business and legal templates for any business task, project or initiative.
Customize your ready-made business document template and save it in the cloud.
Share your files and folders with your team. Create a space of seamless collaboration.
"Fantastic value! I'm not sure how I'd do without it. It's worth its weight in gold and paid back for itself many times."
"I have been using Business in a Box for years. It has been the most useful source of templates I have encountered. I recommend it to anyone."
"It has been a life saver so many times I have lost count. Business in a Box has saved me so much time and as you know, time is money."
Stop downloading documents. Start operating with clarity. Business in a Box gives you the Business Operating System used by over 250,000 companies worldwide to structure, run, and grow their business.
Free Forever Plan · No credit card required
